Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Leukemia, Myeloid, Acute 3Ovarian Neoplasms 2Myelodysplastic Syndromes 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

aldesleukin 22Sunitinib 21Bevacizumab 16Interleukin-2 14Everolimus 14Interferon-alpha 13Gemcitabine 13Cyclophosphamide 13fludarabine phosphate 11Peripheral Blood Stem Cell Transplantation 9Sorafenib 8Filgrastim 8Axitinib 8Nivolumab 7pembrolizumab 6Ipilimumab 6Doxorubicin 6Carboplatin 6sargramostim 5cabozantinib 5Capecitabine 5Thalidomide 4Tacrolimus 4Radiotherapy 4Radiosurgery 4Neoadjuvant Therapy 4Mycophenolic Acid 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Kidney Neoplasms × guadecitabine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡